Gallmetzer Healthcare SpA

Gallmetzer Healthcare SpA

VVIE:GHC
3.42
EUR
-0.32
(-8.56%)
-0.04EPS
56.00MMarket Cap
2025 Y
Revenue per Share
3.7
Basic EPS, GAAP
-0.03
Free Cash Flow per Basic Share
-0.01
Dividend per Share
- -
Book Value per Share
0.5
Tangible Book Value per Share
-0.72
Basic Weighted Avg Shares
16
Sales/Revenue/Turnover
59
Operating Margin (%)
0.09
Depreciation Expense
1
Net Income, GAAP
-1
Effective Tax Rate (%)
- -
Profit Margin (%)
-0.94
Working Capital
-10
LT Debt
2
Total Equity
8
Return on Invested Capital (%)
- -
Return on Capital (%)
- -
Return on Common Equity (%)
- -

Capital Structure

EUR

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

EUR

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
- -
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
59

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
-0.03

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -

Company Description

Sector
Health technology
Industry
Medical specialties
Address
Bolzano Italy
Business
Gallmetzer Healthcare SpA is a medical technology and healthcare solutions provider specializing in the development, manufacture, and distribution of medical devices, hospital equipment, and specialized clinical supplies. Founded in 1982 and headquartered in Bolzano, Italy, the company serves public and private hospitals, outpatient surgery centers, diagnostic laboratories, research institutions, and long-term care facilities across Europe, with primary commercial operations in Italy, Austria, Germany, and Switzerland. The company operates across four principal business divisions: Medical Devices and Surgical Solutions, Infection Prevention and Sterilization Systems, Diagnostics and Laboratory Supplies, and Healthcare Facility Services. Its comprehensive product and service offering includes surgical instrumentation, electrosurgical generators, and wound closure systems; orthopedic implants, trauma fixation devices, and rehabilitation mobility aids; medical-grade autoclaves, ultrasonic cleaning apparatus, chemical indicator monitors, and surface decontamination consumables; in vitro diagnostic test kits, point-of-care analysis hardware, and specimen transport media; patient room furnishings, smart hospital beds, and temperature-controlled medical storage cabinets; and specialized personal protective equipment and custom procedural trays. In addition to product manufacturing and distribution, the company provides biomedical equipment maintenance, regulatory compliance validation, clinical training, and turnkey operating theater engineering services. In recent corporate developments, Gallmetzer Healthcare SpA expanded its international capital profile through its public listing on the Vienna Stock Exchange under the ticker symbol GHC. Over the past two years, the company has implemented significant operational and strategic initiatives, including establishing exclusive European distribution partnerships with international developers of robotic-assisted surgical systems and artificial intelligence-powered diagnostic imaging platforms. To meet growing European demand, the company completed a major expansion of its cleanroom manufacturing facilities and centralized logistics hub in Northern Italy, scaling production of eco-friendly sterile barrier packaging and customized surgical kits. Additionally, Gallmetzer Healthcare SpA completed the strategic acquisition of a regional biomedical engineering services provider and reorganized its distribution framework into dedicated Central European and Mediterranean operating units to accelerate cross-border market penetration.